Cell Adhesion Molecules: Therapeutic Targets for Inhibition of Inflammatory States

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 6, 2015, Pages 563-571

  Allen, Seamus ^a   Moran, Niamh ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

cell adhesion molecules; inflammation; therapeutic strategies

Indexed keywords

ABCIXIMAB; ABRILUMAB; BETA INTEGRIN; CD11B ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; EFALIZUMAB; EPTIFIBATIDE; ETROLIZUMAB; INTEGRIN; LIGAND; NATALIZUMAB; PROTEIN ANTIBODY; TIROFIBAN; VEDOLIZUMAB; MONOCLONAL ANTIBODY; PROTEIN BINDING;

ARTICLE; CELL HOMING; CYTOPLASM; DRUG TARGETING; GENE EXPRESSION; HUMAN; INFLAMMATION; INFLAMMATORY CELL; LEUKOCYTE; NONHUMAN; PEYER PATCH; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; THROMBOSIS; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; BLOOD; CELL ADHESION; CHEMISTRY; CONSERVED SEQUENCE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; MACROPHAGE; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CELL ADHESION; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; CONSERVED SEQUENCE; HUMANS; INFLAMMATION; INTEGRINS; LEUKOCYTES; MACROPHAGES; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84941803889     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0035-1556588     Document Type: Article

References (92)

1. Scarborough R. M. Development of eptifibatide. Am Heart J: 1999; 138 (6 Pt 1): 1093 1104
2. Conrad M. E., Umbreit J. N., Moore E. G. Integrin beta3 blockade with abciximab and protection from myocardial ischemic events. JAMA: 1998; 279 3 195 196
3. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med: 1998; 338 21 1488 1497
4. Cho L., Topol E. J., Balog C., et al. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. J Am Coll Cardiol: 2000; 36 2 381 386
5. Hynes R. O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell: 1992; 69 1 11 25
6. Shimaoka M., Springer T. A. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov: 2003; 2 9 703 716
7. Cox D., Aoki T., Seki J., Motoyama Y., Yoshida K. The pharmacology of the integrins. Med Res Rev: 1994; 14 2 195 228
8. Takada Y., Ye X., Simon S. The integrins. Genome Biol: 2007; 8 5 215
9. Alfsen A., Yu H., Magérus-Chatinet A., Schmitt A., Bomsel M. HIV-1-infected blood mononuclear cells form an integrin- and agrin-dependent viral synapse to induce efficient HIV-1 transcytosis across epithelial cell monolayer. Mol Biol Cell: 2005; 16 9 4267 4279
10. Cox D., Brennan M., Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov: 2010; 9 10 804 820
11. Todd R. F. III. The continuing saga of complement receptor type 3 (CR3). J Clin Invest: 1996; 98 1 1 2
12. Mould A. P., Askari J. A., Humphries M. J. Molecular basis of ligand recognition by integrin alpha 5beta 1. I. Specificity of ligand binding is determined by amino acid sequences in the second and third NH2-terminal repeats of the alpha subunit. J Biol Chem: 2000; 275 27 20324 20336
13. Springer T. A. Folding of the N-terminal, ligand-binding region of integrin alpha-subunits into a beta-propeller domain. Proc Natl Acad Sci U S A: 1997; 94 1 65 72
14. Zhu J., Luo B. H., Xiao T., Zhang C., Nishida N., Springer T. A. Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces. Mol Cell: 2008; 32 6 849 861
15. Liddington R. C., Ginsberg M. H. Integrin activation takes shape. J Cell Biol: 2002; 158 5 833 839
16. Shimaoka M., Salas A., Yang W., Weitz-Schmidt G., Springer T. A. Small molecule integrin antagonists that bind to the beta2 subunit I-like domain and activate signals in one direction and block them in the other. Immunity: 2003; 19 3 391 402
17. Mould A. P., Travis M. A., Barton S. J., et al. Evidence that monoclonal antibodies directed against the integrin beta subunit plexin/semaphorin/integrin domain stimulate function by inducing receptor extension. J Biol Chem: 2005; 280 6 4238 4246
18. Zhu J., Zhu J., Springer T. A. Complete integrin headpiece opening in eight steps. J Cell Biol: 2013; 201 7 1053 1068
19. Xiao T., Takagi J., Coller B. S., Wang J. H., Springer T. A. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature: 2004; 432 7013 59 67
20. Xiong J. P., Stehle T., Zhang R., et al. Crystal structure of the extracellular segment of integrin α Vbeta3 in complex with an Arg-Gly-Asp ligand. Science: 2002; 296 5565 151 155
21. Lau T. L., Kim C., Ginsberg M. H., Ulmer T. S. The structure of the integrin alphaIIbbeta3 transmembrane complex explains integrin transmembrane signalling. EMBO J: 2009; 28 9 1351 1361
22. Luo B. H., Springer T. A., Takagi J. A specific interface between integrin transmembrane helices and affinity for ligand. PLoS Biol: 2004; 2 6 e153
23. Wang W., Zhu J., Springer T. A., Luo B. H. Tests of integrin transmembrane domain homo-oligomerization during integrin ligand binding and signaling. J Biol Chem: 2011; 286 3 1860 1867
24. Yin H., Litvinov R. I., Vilaire G., et al. Activation of platelet alphaIIbbeta3 by an exogenous peptide corresponding to the transmembrane domain of alphaIIb. J Biol Chem: 2006; 281 48 36732 36741
25. Stephens G., O'Luanaigh N., Reilly D., et al. A sequence within the cytoplasmic tail of GpIIb independently activates platelet aggregation and thromboxane synthesis. J Biol Chem: 1998; 273 32 20317 20322
26. Sastry S. K., Horwitz A. F. Integrin cytoplasmic domains: mediators of cytoskeletal linkages and extra- and intracellular initiated transmembrane signaling. Curr Opin Cell Biol: 1993; 5 5 819 831
27. Larkin D., Murphy D., Reilly D. F., et al. ICln, a novel integrin alphaIIbbeta3-associated protein, functionally regulates platelet activation. J Biol Chem: 2004; 279 26 27286 27293
28. Brophy T. M., Raab M., Daxecker H., et al. RN181, a novel ubiquitin E3 ligase that interacts with the KVGFFKR motif of platelet integrin α(IIb)β3. Biochem Biophys Res Commun: 2008; 369 4 1088 1093
29. Liu S., Thomas S. M., Woodside D. G., et al. Binding of paxillin to α4 integrins modifies integrin-dependent biological responses. Nature: 1999; 402 6762 676 681
30. Li A., Guo Q., Kim C., Hu W., Ye F. Integrin αII b tail distal of GFFKR participates in inside-out αII b β3 activation. J Thromb Haemost: 2014; 12 7 1145 1155
31. Liu S., Calderwood D. A., Ginsberg M. H. Integrin cytoplasmic domain-binding proteins. J Cell Sci: 2000; 113 (Pt 20): 3563 3571
32. Hughes P. E., Diaz-Gonzalez F., Leong L., et al. Breaking the integrin hinge. A defined structural constraint regulates integrin signaling. J Biol Chem: 1996; 271 12 6571 6574
33. Anthis N. J., Haling J. R., Oxley C. L., et al. Beta integrin tyrosine phosphorylation is a conserved mechanism for regulating talin-induced integrin activation. J Biol Chem: 2009; 284 52 36700 36710
34. Law D. A., DeGuzman F. R., Heiser P., Ministri-Madrid K., Killeen N., Phillips D. R. Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function. Nature: 1999; 401 6755 808 811
35. Blystone S. D., Williams M. P., Slater S. E., Brown E. J. Requirement of integrin beta3 tyrosine 747 for beta3 tyrosine phosphorylation and regulation of alphavbeta3 avidity. J Biol Chem: 1997; 272 45 28757 28761
36. Sakai T., Zhang Q., Fässler R., Mosher D. F. Modulation of beta1A integrin functions by tyrosine residues in the beta1 cytoplasmic domain. J Cell Biol: 1998; 141 2 527 538
37. Calderwood D. A., Fujioka Y., de Pereda J. M., et al. Integrin beta cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling. Proc Natl Acad Sci U S A: 2003; 100 5 2272 2277
38. Naik U. P., Patel P. M., Parise L. V. Identification of a novel calcium-binding protein that interacts with the integrin alphaIIb cytoplasmic domain. J Biol Chem: 1997; 272 8 4651 4654
39. Vijayan K. V., Liu Y., Li T. T., Bray P. F. Protein phosphatase 1 associates with the integrin alphaIIb subunit and regulates signaling. J Biol Chem: 2004; 279 32 33039 33042
40. Gushiken F. C., Patel V., Liu Y., et al. Protein phosphatase 2A negatively regulates integrin alpha(IIb)beta(3) signaling. J Biol Chem: 2008; 283 19 12862 12869
41. Kato A., Kawamata N., Tamayose K., et al. Ancient ubiquitous protein 1 binds to the conserved membrane-proximal sequence of the cytoplasmic tail of the integrin alpha subunits that plays a crucial role in the inside-out signaling of alpha IIbbeta 3. J Biol Chem: 2002; 277 32 28934 28941
42. Liu Q. Y., Corjay M., Feuerstein G. Z., Nambi P. Identification and characterization of triosephosphate isomerase that specifically interacts with the integrin alphaIIb cytoplasmic domain. Biochem Pharmacol: 2006; 72 5 551 557
43. Deshmukh L., Tyukhtenko S., Liu J., Fox J. E., Qin J., Vinogradova O. Structural insight into the interaction between platelet integrin alphaIIbbeta3 and cytoskeletal protein skelemin. J Biol Chem: 2007; 282 44 32349 32356
44. Chua G. L., Patra A. T., Tan S. M., Bhattacharjya S. NMR structure of integrin α4 cytosolic tail and its interactions with paxillin. PLoS ONE: 2013; 8 1 e55184
45. Calderwood D. A. Talin controls integrin activation. Biochem Soc Trans: 2004; 32 (Pt3): 434 437
46. Wegener K. L., Partridge A. W., Han J., et al. Structural basis of integrin activation by talin. Cell: 2007; 128 1 171 182
47. Moser M., Legate K. R., Zent R., Fässler R. The tail of integrins, talin, and kindlins. Science: 2009; 324 5929 895 899
48. Harburger D. S., Bouaouina M., Calderwood D. A. Kindlin-1 and -2 directly bind the C-terminal region of beta integrin cytoplasmic tails and exert integrin-specific activation effects. J Biol Chem: 2009; 284 17 11485 11497
49. Fagerholm S. C., Lek H. S., Morrison V. L. Kindlin-3 in the immune system. Am J Clin Exp Immunol: 2014; 3 1 37 42
50. Takala H., Nurminen E., Nurmi S. M., et al. Beta2 integrin phosphorylation on Thr758 acts as a molecular switch to regulate 14-3-3 and filamin binding. Blood: 2008; 112 5 1853 1862
51. Hart R., Stanley P., Chakravarty P., Hogg N. The kindlin 3 pleckstrin homology domain has an essential role in lymphocyte function-associated antigen 1 (LFA-1) integrin-mediated B cell adhesion and migration. J Biol Chem: 2013; 288 21 14852 14862
52. Gruda R., Brown A. C., Grabovsky V., et al. Loss of kindlin-3 alters the threshold for NK cell activation in human leukocyte adhesion deficiency-III. Blood: 2012; 120 19 3915 3924
53. Moretti F. A., Moser M., Lyck R., et al. Kindlin-3 regulates integrin activation and adhesion reinforcement of effector T cells. Proc Natl Acad Sci U S A: 2013; 110 42 17005 17010
54. Morrison V. L., MacPherson M., Savinko T., Lek H. S., Prescott A., Fagerholm S. C. The β2 integrin-kindlin-3 interaction is essential for T-cell homing but dispensable for T-cell activation in vivo. Blood: 2013; 122 8 1428 1436
55. Kasirer-Friede A., Kang J., Kahner B., Ye F., Ginsberg M. H., Shattil S. J. ADAP interactions with talin and kindlin promote platelet integrin αIIbβ3 activation and stable fibrinogen binding. Blood: 2014; 123 20 3156 3165
56. Hayward A. R., Harvey B. A., Leonard J., Greenwood M. C., Wood C. B., Soothill J. F. Delayed separation of the umbilical cord, widespread infections, and defective neutrophil mobility. Lancet: 1979; 1 8126 1099 1101
57. Crowley C. A., Curnutte J. T., Rosin R. E., et al. An inherited abnormality of neutrophil adhesion. Its genetic transmission and its association with a missing protein. N Engl J Med: 1980; 302 21 1163 1168
58. Marlin S. D., Morton C. C., Anderson D. C., Springer T. A. LFA-1 immunodeficiency disease. Definition of the genetic defect and chromosomal mapping of alpha and beta subunits of the lymphocyte function-associated antigen 1 (LFA-1) by complementation in hybrid cells. J Exp Med: 1986; 164 3 855 867
59. Etzioni A., Harlan J. M., Pollack S., Phillips L. M., Gershoni-Baruch R., Paulson J. C. Leukocyte adhesion deficiency (LAD) II: a new adhesion defect due to absence of sialyl Lewis X, the ligand for selectins. Immunodeficiency: 1993; 4 1-4 307 308
60. Etzioni A. Defects in the leukocyte adhesion cascade. Clin Rev Allergy Immunol: 2010; 38 1 54 60
61. Larson R. S., Hibbs M. L., Springer T. A. The leukocyte integrin LFA-1 reconstituted by cDNA transfection in a nonhematopoietic cell line is functionally active and not transiently regulated. Cell Regul: 1990; 1 4 359 367
62. Schürpf T., Springer T. A. Regulation of integrin affinity on cell surfaces. EMBO J: 2011; 30 23 4712 4727
63. Peroni D. G., Djukanović R., Bradding P., et al. Expression of CD44 and integrins in bronchial mucosa of normal and mildly asthmatic subjects. Eur Respir J: 1996; 9 11 2236 2242
64. Zimmerman T., Blanco F. J. Inhibitors targeting the LFA-1/ICAM-1 cell-adhesion interaction: design and mechanism of action. Curr Pharm Des: 2008; 14 22 2128 2139
65. Plow E. F., Zhang L. A MAC-1 attack: integrin functions directly challenged in knockout mice. J Clin Invest: 1997; 99 6 1145 1146
66. Solovjov D. A., Pluskota E., Plow E. F. Distinct roles for the alpha and beta subunits in the functions of integrin alphaMbeta2. J Biol Chem: 2005; 280 2 1336 1345
67. Noti J. D., Johnson A. K., Dillon J. D. The leukocyte integrin gene CD11d is repressed by gut-enriched Kruppel-like factor 4 in myeloid cells. J Biol Chem: 2005; 280 5 3449 3457
68. Noti J. D. Expression of the myeloid-specific leukocyte integrin gene CD11d during macrophage foam cell differentiation and exposure to lipoproteins. Int J Mol Med: 2002; 10 6 721 727
69. Miyazaki Y., Bunting M., Stafforini D. M., et al. Integrin alphaDbeta2 is dynamically expressed by inflamed macrophages and alters the natural history of lethal systemic infections. J Immunol: 2008; 180 1 590 600
70. Postigo A. A., Pulido R., Campanero M. R., et al. Differential expression of VLA-4 integrin by resident and peripheral blood B lymphocytes. Acquisition of functionally active alpha 4 beta 1-fibronectin receptors upon B cell activation. Eur J Immunol: 1991; 21 10 2437 2445
71. Millard M., Odde S., Neamati N. Integrin targeted therapeutics. Theranostics: 2011; 1 154 188
72. Marazuela M., Postigo A. A., Acevedo A., Díaz-González F., Sanchez-Madrid F., de Landázuri M. O. Adhesion molecules from the LFA-1/ICAM-1,3 and VLA-4/VCAM-1 pathways on T lymphocytes and vascular endothelium in Graves' and Hashimoto's thyroid glands. Eur J Immunol: 1994; 24 10 2483 2490
73. Laschinger M., Engelhardt B. Interaction of alpha4-integrin with VCAM-1 is involved in adhesion of encephalitogenic T cell blasts to brain endothelium but not in their transendothelial migration in vitro. J Neuroimmunol: 2000; 102 1 32 43
74. Sun H., Liu J., Zheng Y., Pan Y., Zhang K., Chen J. Distinct chemokine signaling regulates integrin ligand specificity to dictate tissue-specific lymphocyte homing. Dev Cell: 2014; 30 1 61 70
75. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med: 1998; 339 7 436 443
76. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med: 1994; 330 14 956 961
77. Artoni A., Li J., Mitchell B., et al. Integrin β3 regions controlling binding of murine mAb 7E3: implications for the mechanism of integrin alphaIIbbeta3 activation. Proc Natl Acad Sci U S A: 2004; 101 36 13114 13120
78. Stüve O., Bennett J. L. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev: 2007; 13 1 79 95
79. Rice G. P., Hartung H. P., Calabresi P. A. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology: 2005; 64 8 1336 1342
80. Fedyk E. R., Wyant T., Yang L. L., et al. Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis: 2012; 18 11 2107 2119
81. Yao K., Gagnon S., Akhyani N., et al. Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. PLoS ONE: 2008; 3 4 e2028
82. Bloomgren G., Richman S., Hotermans C., et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med: 2012; 366 20 1870 1880
83. Picarella D., Hurlbut P., Rottman J., Shi X., Butcher E., Ringler D. J. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol: 1997; 158 5 2099 2106
84. Danese S., Panés J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology: 2014; 147 5 981 989
85. Garnock-Jones K. P. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease. Bio Drugs: 2015; 29 1 57 67
86. Jullien D., Prinz J. C., Langley R. G., et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology: 2004; 208 4 297 306
87. Frampton J. E., Plosker G. L. Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis. Am J Clin Dermatol: 2009; 10 1 51 72
88. Wang L. C., Wang I. H., Jou J. R. Optic neuritis secondary to Angiostrongylus cantonensis infection. Ocul Immunol Inflamm: 2006; 14 3 189 191
89. Vanderslice P., Woodside D. G. Integrin antagonists as therapeutics for inflammatory diseases. Expert Opin Investig Drugs: 2006; 15 10 1235 1255
90. Halland N., Blum H., Buning C., Kohlmann M., Lindenschmidt A. Small Macrocycles As Highly Active Integrin α2β1 Antagonists. ACS Med Chem Lett: 2014; 5 2 193 198
91. Grove R. A., Shackelford S., Sopper S., et al. Leukocyte counts in cerebrospinal fluid and blood following firategrast treatment in subjects with relapsing forms of multiple sclerosis. Eur J Neurol: 2013; 20 7 1032 1042
92. Sedgwick J. B., Jansen K. J., Kennedy J. D., Kita H., Busse W. W. Effects of the very late adhesion molecule 4 antagonist WAY103 on human peripheral blood eosinophil vascular cell adhesion molecule 1-dependent functions. J Allergy Clin Immunol: 2005; 116 4 812 819.